Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

Pharmacogenomics Journal

Volumn 1, Issue 1, 2001, Pages 65-70

  Pullarkat, S T ^a   Lenz, H J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

5 fu resistance; Colorectal cancer; Fluoropyrimidine chemotherapy; Ts gene expression; Ts polymorphlsrn

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; MESSENGER RNA; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RNA, MESSENGER; THYMIDYLATE SYNTHASE;

EID: 0035750549     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500012     Document Type: Article

References (3)

1. Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391-399.
2. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136-1143.
3. Heidelberger C, Chaudhuri NX, Danneberg P, Mooren D, Griesbach L, Dushinsky R et al. Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 1957; 179: 663-666.